Advaxis, Inc. Engages SynCo Bio Partners B.V. For Manufacturing Of ADXS-HPV, Its Lead Cancer Immunotherapy Program
Published: Feb 11, 2014
PRINCETON, N.J., Feb. 11, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, and SynCo Bio Partners B.V. (SynCo), one of the leading GMP contract manufacturers of biopharmaceuticals, announced today that they have signed an agreement for SynCo to manufacture Advaxis' novel drug candidate, ADXS-HPV. Under the agreement, SynCo will assist Advaxis in developing scale-up and commercial manufacturing processes for ADXS-HPV bulk drug substance and drug product. Advaxis plans to initiate registrational trials this year with ADXS-HPV for the treatment of cervical cancer.
Help employers find you! Check out all the jobs and post your resume.